tirzepatide surmount-1 weight loss percent 72 weeks results Trial New GLP-1 clinical trial data
Description
The agency also noted that Zepbound causes thyroid C-cell tumors in rats, but it's unclear if the drug has that effect in humans
This corresponded to a risk difference of 0.3% (95% CI 0.4% to 0.1%) and a hazard ratio of 0.82 (95% CI 0.74 to 0.91) (Fig
In the quest for more effective treatments for diabetes, researchers have developed a groundbreaking solution that could revolutionize the way this chronic condition is managed
Expect early discomfort, financial commitment, and a shift in thinking about weight as a chronic condition rather than a temporary problem
The Verdict Who Should Switch, and Who Shouldn't
